Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00119639
First received: July 8, 2005
Last updated: January 15, 2009
Last verified: January 2009
  Purpose

This is a 400 mg (2 x 200 mg tablets) sorafenib single dose, open-label study being conducted to compare the pharmacokinetics of plasma and urine and safety of sorafenib in subjects with severe, moderate, and mild renal impairment with those exhibiting normal renal function.


Condition Intervention Phase
Kidney Diseases
Drug: Sorafenib (BAY43-9006, Nexavar)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of Sorafenib (BAY 43-9006, Nexavar).

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Pharmacokinetics of sorafenib in plasma and urine; single-dose safety of sorafenib in patients with renal impairment [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 32
Study Start Date: June 2005
Study Completion Date: December 2005
Arms Assigned Interventions
Experimental: Arm 1 Drug: Sorafenib (BAY43-9006, Nexavar)
All subjects were given a open-label, single dose of 400mg sorafenib

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Post menopausal females
  • Surgically sterile females
  • Body Mass Index between 18-37
  • Subjects with Clcr greater than 80 mL/min
  • Subjects with Clcr 50 to 80 mL/min
  • Subjects with Clcr 30 to 50 mL/min
  • Clcr less than 30 mL/min but not on dialysis
  • Subjects must test negative for HIV
  • Subjects must test negative for drugs of abuse at screening

Exclusion Criteria:

All Subjects :

  • Concomitant Medication: Treatment with CYP3A4 inducers, such as rifampin and St. John's Wort within 14 days of Day 1 until they leave the clinic on Day 7
  • Donation of blood within 30 days of Day 1
  • Recent participation in an investigational drug study during which active medication was given within 30 days of Day 1
  • History of gastrointestinal disorder that could result in incomplete absorption of study drug
  • Malignancy
  • Significant neurologic or psychiatric disorders
  • History of drug or alcohol abuse in year prior to screening for this trial, or current intake or >14 standard alcoholic drinks per week
  • Prior history of epilepsy or other seizure disorders
  • Known hypersensitivity to inhibitors of raf kinase or VEGFR-2
  • Females of child-bearing potential
  • Smoking > 10 cigarettes/day or equivalent
  • Excessive consumption (more than five 8-oz. cups/day) of coffee or caffeine

Healthy Volunteer:

  • Existing failure of a major organ system, or a medical disorder that would impair the subject's ability to complete the study (in the opinion of the investigator or the sponsor), eg history of blood coagulation disorders
  • Hematocrit value < 34% in the control group at screening

Renal Impairment Groups:

  • Existing failure of a major organ system or a medical disorder (other than the target disease) which would impair the subject's ability to complete the study (in the opinion of the investigator or the sponsor)
  • Concomitant Medication: Renal impairment subjects taking phosphate binders, ion exchange resins and/or iron supplements may take them with their meals, but must withhold them on the morning of Day 1 (dosing day) until after their 4 hour post-dose tests and procedures are performed.
  • Myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angiography within 6 months of Day 1; unstable angina; uncontrolled significant hypertension within 3 months of Day 1; cerebral vascular accident or transient ischemic attack within 12 months of Day 1
  • Subjects with hypertension who have had a medication or dose change within one week of Day 1
  • Subjects requiring dialysis
  • Subjects with kidney transplants
  • Liver transaminase (AST, ALT) greater than 5 times the ULN at screening; any active liver disease or unexplained or persistent elevations in liver function tests
  • Hematocrit value < 24% in the renal impaired groups
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00119639

Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Head Clinical Pharmacology, Bayer Healthcare Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT00119639     History of Changes
Other Study ID Numbers: 11804
Study First Received: July 8, 2005
Last Updated: January 15, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Sorafenib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014